Biodel announces positive top-line results from Phase I RHI trial
The products achieved the target pharmacokinetic, pharmacodynamic and toleration profiles in a Phase I trial and BIOD-123 is expected to advance to Phase II in the third calendar
US-based gene therapy biotech Seawolf Therapeutics and Sanofi have signed a multi-target research partnership and exclusive licensing deal worth up to $1.2bn to develop treatments for bleeding disorders and other undisclosed indications.
The FDA-approved Adcetris is an Antibody Drug Conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE),